Oncologists saw a mixed bag of late-breaking data as companies reported both setbacks and trial progress across solid tumors and targeted approaches. AstraZeneca also posted disappointing late-stage results for Etcamah (an estrogen/progesterone receptor pathway SERD, per the report), with the company saying the drug failed a Phase III study intended to support a label expansion earlier in the treatment setting. Elsewhere, MediLink reported a Phase III win in small-cell lung cancer with a Roche-partnered B7-H3-directed antibody-drug conjugate, though cross-trial survival comparisons trailed GSK’s rival asset. Separately, Triana Biomedicines disclosed preclinical results positioning its brain-penetrant ALK fusion protein degrader TRI-611 as an alternative to ALK TKIs, using a molecular glue mechanism that draws ALK to cereblon for degradation.